Masuda N, Fukuoka M, Furuse K
Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.
Oncology. 1992;49 Suppl 1:19-24. doi: 10.1159/000227106.
CODE therapy demonstrated high antitumor activity in extensive-stage small cell lung cancer (SCLC). Toxicity was acceptable in a regimen with a nine-cycle schedule. The results obtained in this study suggest that CODE therapy improves the outcome of patients with extensive-stage SCLC. The use of recombinant human granulocyte colony-stimulating factor may well reduce the duration and degree of neutropenia during CODE chemotherapy and increase the dose intensity, leading to further improvement of outcome.
CODE疗法在广泛期小细胞肺癌（SCLC）中显示出高抗肿瘤活性。在一个九周期方案中，毒性是可接受的。本研究获得的结果表明，CODE疗法可改善广泛期SCLC患者的预后。使用重组人粒细胞集落刺激因子很可能会缩短CODE化疗期间中性粒细胞减少的持续时间并减轻其程度，提高剂量强度，从而进一步改善预后。
